Jose Jobin, Rafeek Naziya Refi
Department of Pharmaceutical Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, NITTE Deemed to be University, Mangalore, Karnataka, India.
Ther Innov Regul Sci. 2019 Nov;53(6):781-786. doi: 10.1177/2168479018812775. Epub 2018 Dec 17.
Pharmacovigilance (PV) is an integral part of the drug regulation system. PV plays an indispensable role in the identification, assessment, and publicizing of adverse drug reactions (ADRs) through various methods. ADRs account for serious harm to the patients and even lead to morbidity and mortality. The PV databases help in the promotion of safe drug use and protection of public health safety. This article compares the PV system in the USA, Europe, and India, highlighting the challenges and future perspectives to be adapted to widen the horizon of the existing PV structure in India. In India, PV programs are still at the dawning stage when paralleled to the other countries. The National Pharmacovigilance Program and the Pharmacovigilance Program of India are the most recent advancements in this field in the country. The USA and Europe have well-established PV systems in place thanks to technological progress and other resources. India is the largest producer of pharmaceuticals in the world and a major clinical research hub; hence, it requires a more stringent PV setup. With the increase in population and novel drugs in the market each day, there is a need for an effective PV system in India.
药物警戒(PV)是药品监管体系不可或缺的一部分。药物警戒通过多种方法在药品不良反应(ADR)的识别、评估及公布方面发挥着不可或缺的作用。药品不良反应会对患者造成严重伤害,甚至导致发病和死亡。药物警戒数据库有助于促进安全用药及保护公众健康安全。本文比较了美国、欧洲和印度的药物警戒体系,重点阐述了为拓宽印度现有药物警戒架构视野而需应对的挑战及未来展望。与其他国家相比,印度的药物警戒项目仍处于起步阶段。国家药物警戒计划和印度药物警戒计划是该国该领域的最新进展。由于技术进步和其他资源,美国和欧洲已建立了完善的药物警戒体系。印度是世界上最大的药品生产国和主要的临床研究中心;因此,它需要一个更严格的药物警戒体系。随着人口的增长以及市场上新药的日益增多,印度需要一个有效的药物警戒体系。